Revolution Medicines

Revolution's pan-RAS drug clears path to Phase III in pancreatic cancer
First Word Pharma
Mon, 07/15/24 - 11:24 pm
Revolution Medicines
RMC-6236
pancreatic cancer
EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing
BioPharma Dive
Wed, 08/2/23 - 10:23 am
EQRx
drug pricing
Revolution Medicines
Sanofi sets Revolution back, sending $550M SHP2 inhibitor deal to the docks
Fierce Biotech
Fri, 12/9/22 - 10:26 am
Sanofi
Revolution Medicines
SHP2 inhibitors
RMC-4630
Covid-19 stalls biotech flotations
EP Vantage
Fri, 04/10/20 - 10:26 am
COVID-19
IPOs
Revolution Medicines
Black Diamond Therapeutics
Passage Bio
Beam Therapeutics
Schrödinger
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
Xconomy
Thu, 02/13/20 - 12:06 am
IPOs
RAS
cancer
Revolution Medicines
Oncology biotech Revolution Medicines sets terms for $150 million IPO
NASDAQ
Mon, 02/3/20 - 10:27 am
Revolution Medicines
IPOs
oncology
RAS pathway
Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program
Endpoints
Wed, 07/18/18 - 10:29 pm
Sanofi
Revolution Medicines
cancer
The 2015 Fierce 15 biotech execs take a bow
Fierce Biotech
Sat, 10/3/15 - 02:01 pm
Alector
Arvinas
CRISPR Therapeutics
Intellia Therapeutics
NGM Biopharmaceuticals
Padlock Therapeutics
SQZ Biotech
Revolution Medicines
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics